Takeda, Twist partner on biologics discovery

By The Science Advisory Board staff writers

July 9, 2020 -- Twist Bioscience and Takeda Pharmaceutical have formed a partnership for access to Twist's proprietary phage display libraries for the discovery of antibodies in Takeda's biologics pipeline.

Under the agreement, Twist Biopharma will license Takeda its "Library of Libraries," a panel of synthetic antibody phage display libraries derived from human genetic sequences. Together, the companies will work to discover, validate, and optimize new antibody candidates for applications in oncology, rare diseases, neuroscience, and gastroenterology. Takeda will pay Twist annual technology licensing fees, as well as milestone payments and royalties for all compounds discovered from using Twist's phage display libraries.

Carmine, Takeda use extracellular vesicles for rare disease gene therapies
Carmine Therapeutics has signed a research collaboration agreement with Takeda Pharmaceutical to develop gene therapies for rare diseases.
Egle, Takeda collaborate on anti-Treg immunotherapies
Egle Therapeutics has formed a strategic research alliance with Takeda Pharmaceutical to validate novel regulatory T-cell (Treg) targets, against which...
Twist, Serimmune identify SARS-CoV-2 antibody therapies
Twist Bioscience has joined forces with Serimmune to identify and evaluate SARS-CoV-2 therapeutic antibody candidates.
Twist Bioscience partners with Miroculus on clinical products
Synthetic biology company Twist Bioscience announced on February 25 that it has initiated a collaboration with digital microfluidics developer Miroculus...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter